Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer

Journal of Surgical Oncology

Volumn 104, Issue 3, 2011, Pages 305-311

  Vashist, Yogesh K ^a   Uzungolu, Guentac ^a   Kutup, Asad ^a   Gebauer, Florian ^a   Koenig, Alexandra ^a   Deutsch, Lena ^a   Zehler, Oliver ^a   Busch, Philipp ^a   Kalinin, Viacheslav ^a   Izbicki, Jakob R ^a   Yekebas, Emre F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

germ line polymorphism; heme oxygenase 1; pancreatic cancer; prognostic marker

Indexed keywords

HEME OXYGENASE 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; ELECTROPHORESIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HUMAN; LEUKOCYTE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOCARCINOMA; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENOTYPE; GERM CELLS; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80051551016     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21926     Document Type: Article

References (64)

1. Bramhall SR, Allum WH, Jones AG, et al.: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 1995; 82: 111-115.
2. Cameron JL, Riall TS, Coleman J, et al.: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15. (Pubitemid 44297442)
3. Sener SF, Fremgen A, Menck HR, et al.: Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999; 189: 1-7. (Pubitemid 29307735)
4. Dunphy EP,: Pancreatic cancer: A review and update. Clin J Oncol Nurs 2008; 12: 735-741.
5. Ghaneh P, Smith R, Tudor-Smith C, et al.: Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 2008; 34: 297-305. (Pubitemid 351312868)
6. Ujiki MB, Talamonti MS,: Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol 2007; 34: 311-320. (Pubitemid 47176619)
7. Wolff RA, Varadhachary GR, Evans DB,: Adjuvant therapy for adenocarcinoma of the pancreas: Analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008; 15: 2773-2786.
8. Katz MH, Hwang R, Fleming JB, et al.: Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 2008; 58: 111-125. (Pubitemid 351521866)
9. Zuckerman DS, Ryan DP,: Adjuvant therapy for pancreatic cancer: A review. Cancer 2008; 112: 243-249.
10. Gutt R, Liauw SL, Weichselbaum RR,: Adjuvant radiotherapy for resected pancreatic cancer: A lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol 2009; 6: 38-46.
11. Iott MJ, Corsini MM, Miller RC,: Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas. Clin J Oncol Nurs 2008; 12: 599-605.
12. Gouma DJ, Busch OR, van Gulik TM,: Treatment of pancreatic adenocarcinoma: A European perspective. Surg Oncol Clin N Am 2008; 17: 569-586, ix. (Pubitemid 351672068)
13. Grote T, Logsdon CD,: Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 2007; 23: 508-514. (Pubitemid 47356736)
14. Chang CY, Huang SP, Chiu HM, et al.: Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006; 53: 1-4.
15. Kilic M, Gocmen E, Tez M, et al.: Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006; 49: 241-244. (Pubitemid 44432800)
16. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327. (Pubitemid 46631379)
17. Verbeke CS,: Resection margins and R1 rates in pancreatic cancer-Are we there yet? Histopathology 2008; 52: 787-796. (Pubitemid 351724902)
18. Verbeke CS, Leitch D, Menon KV, et al.: Redefining the R1 resection in pancreatic cancer. Br J Surg 2006; 93: 1232-1237. (Pubitemid 44547022)
19. Verbeke CS, Menon KV,: Variability in reporting resection margin status in pancreatic cancer. Ann Surg 2008; 247: 716-717. (Pubitemid 351440631)
20. Idriss NK, Blann AD, Lip GY,: Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol 2008; 52: 971-978.
21. Immenschuh S, Ramadori G,: Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 2000; 60: 1121-1128.
22. Jarmi T, Agarwal A,: Heme oxygenase and renal disease. Curr Hypertens Rep 2009; 11: 56-62.
23. Jozkowicz A, Was H, Dulak J,: Heme oxygenase-1 in tumors: Is it a false friend? Antioxid Redox Signal 2007; 9: 2099-2117. (Pubitemid 350059009)
24. Prawan A, Kundu JK, Surh YJ,: Molecular basis of heme oxygenase-1 induction: Implications for chemoprevention and chemoprotection. Antioxid Redox Signal 2005; 7: 1688-1703. (Pubitemid 41768002)
25. Doi K, Akaike T, Fujii S, et al.: Induction of haem oxygenase-1 nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 1999; 80: 1945-1954. (Pubitemid 29391278)
26. Fang J, Akaike T, Maeda H,: Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 2004; 9: 27-35. (Pubitemid 38270426)
27. Hill M, Pereira V, Chauveau C, et al.: Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: Mutual cross inhibition with indoleamine 2,3-dioxygenase. Faseb J 2005; 19: 1957-1968. (Pubitemid 41759741)
28. Liu ZM, Chen GG, Ng EK, et al.: Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells. Oncogene 2004; 23: 503-513. (Pubitemid 38175005)
29. Rushworth SA, MacEwan DJ,: HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008; 111: 3793-3801.
30. Berberat PO, Dambrauskas Z, Gulbinas A, et al.: Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005; 11: 3790-3798. (Pubitemid 40685598)
31. Nuhn P, Kunzli BM, Hennig R, et al.: Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer 2009; 8: 37.
32. Schwer CI, Guerrero AM, Humar M, et al.: Heme oxygenase-1 inhibits the proliferation of pancreatic stellate cells by repression of the extracellular signal-regulated kinase1/2 pathway. J Pharmacol Exp Ther 2008; 327: 863-871.
33. Sunamura M, Duda DG, Ghattas MH, et al.: Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003; 6: 15-24. (Pubitemid 37305335)
34. Exner M, Minar E, Wagner O, et al.: The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004; 37: 1097-1104. (Pubitemid 39296737)
35. Yamada N, Yamaya M, Okinaga S, et al.: Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66: 187-195. (Pubitemid 30481482)
36. Chang KW, Lee TC, Yeh WI, et al.: Polymorphism in heme oxygenase-1 (HO-1) promoter is related to the risk of oral squamous cell carcinoma occurring on male areca chewers. Br J Cancer 2004; 91: 1551-1555.
37. Kikuchi A, Yamaya M, Suzuki S, et al.: Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. Hum Genet 2005; 116: 354-360. (Pubitemid 40521111)
38. Okamoto I, Krogler J, Endler G, et al.: A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with risk for melanoma. Int J Cancer 2006; 119: 1312-1315. (Pubitemid 44258805)
39. Sawa T, Mounawar M, Tatemichi M, et al.: Increased risk of gastric cancer in Japanese subjects is associated with microsatellite polymorphisms in the heme oxygenase-1 and the inducible nitric oxide synthase gene promoters. Cancer Lett 2008; 269: 78-84.
40. Vashist YK, Blessmann M, Trump F, et al.: Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients. J Oral Pathol Med 2008; 37: 480-484.
41. Vashist YK, Uzunoglu G, Cataldegirmen G, et al.: Haeme oxygenase-1 promoter polymorphism is an independent prognostic marker of gastrointestinal stromal tumour. Histopathology 2009; 54: 303-308.
42. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Validation of the 6th edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007; 110: 738-744. (Pubitemid 47257648)
43. Esposito I, Kleeff J, Bergmann F, et al.: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 15: 1651-1660.
44. Oldenhuis CN, Oosting SF, Gietema JA, et al.: Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44: 946-953.
45. Petersen GM, Amundadottir L, Fuchs CS, et al.: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228.
46. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al.: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41: 986-990.
47. Antoniou AC, Spurdle AB, Sinilnikova OM, et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82: 937-948.
48. Kraft P, Pharoah P, Chanock SJ, et al.: Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005; 1: e68.
49. Adjadj E, Schlumberger M, de Vathaire F,: Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer. Lancet Oncol 2009; 10: 181-190.
50. Okazaki T, Javle M, Tanaka M, et al.: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-329.
51. Tanaka M, Javle M, Dong X, et al.: Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116: 5325-5335. DOI: 10.1002/cncr.25282.
52. Innocenti F, Undevia SD, Iyer L, et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388. (Pubitemid 41103619)
53. DeMichele A, Aplenc R, Botbyl J, et al.: Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005; 23: 5552-5559.
54. Innocenti F, Iyer L, Ratain MJ,: Pharmacogenetics: A tool for individualizing antineoplastic therapy. Clin Pharmacokinet 2000; 39: 315-325.
55. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, et al.: Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 2007; 9: R78.
56. Hunter KW,: Host genetics and tumour metastasis. Br J Cancer 2004; 90: 752-755. (Pubitemid 38406581)
57. Van Ness B, Ramos C, Haznadar M, et al.: Genomic variation in myeloma: Design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
58. Gleixner KV, Mayerhofer M, Vales A, et al.: Targeting of Hsp32 in solid tumors and leukemias: A novel approach to optimize anticancer therapy. Curr Cancer Drug Targets 2009; 9: 675-689.
59. Naylor LH, Clark EM,: d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription. Nucleic Acids Res 1990; 18: 1595-1601.
60. Brandt B, Meyer-Staeckling S, Schmidt H, et al.: Mechanisms of egfr gene transcription modulation: Relationship to cancer risk and therapy response. Clin Cancer Res 2006; 12: 7252-7260. (Pubitemid 46095396)
61. Buerger H, Packeisen J, Boecker A, et al.: Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol 2004; 203: 545-550. (Pubitemid 38529034)
62. Gebhardt F, Burger H, Brandt B,: Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-A link between genetics and epigenetics. Histol Histopathol 2000; 15: 929-936. (Pubitemid 30488572)
63. Gebhardt F, Burger H, Brandt B,: Modulation of EGFR gene transcription by a polymorphic repetitive sequence-A link between genetics and epigenetics. Int J Biol Markers 2000; 15: 105-110. (Pubitemid 30195494)
64. Yamaya M, Nakayama K, Ebihara S, et al.: Relationship between microsatellite polymorphism in the haem oxygenase-1 gene promoter and longevity of the normal Japanese population. J Med Genet 2003; 40: 146-148. (Pubitemid 36232822)